GlassScriptPhysician profile
Mei Huang
NPI 1417972597
$2,785.30
in general payments reported to CMS, 2019-2025
22 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.49 · 2021: $143 · 2022: $231 · 2023: $936 · 2024: $1,192 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $560.12 | 2022-2025 | Stelara, Tremfya |
| Abbvie INC. | $424.02 | 2021-2025 | |
| Genzyme Corporation | $367.81 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.01 | 2022-2025 | Trulance, Xifaxan |
| Aimmune Therapeutics, INC. | $198.65 | 2024-2025 | Vowst, Zenpep |
| Nestle Healthcare Nutrition INC. | $126.24 | 2021-2023 | |
| Pfizer INC. | $125.84 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.74 | 2021-2024 | Entyvio, Gattex |
| Ardelyx, INC. | $97.06 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $91.50 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $86.29 | 2021-2024 | Dificid, Zerbaxa, Recarbrio |
| Gilead Sciences, INC. | $78.52 | 2019-2022 | |
| Lilly USA, LLC | $75.67 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $39.95 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Braintree Laboratories, INC. | $35.76 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $31.86 | 2024 | Fujifilm |
| Capsovision, INC. | $20.16 | 2023 | Capsocam Plus |
| Madrigal Pharmaceuticals | $20.04 | 2024 | Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.31 | 2023 | Cyltezo |
| Celgene Corporation | $18.20 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $15.81 | 2023 | Linzess |
| Amarin Pharma, INC. | $12.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mei Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.